The IPO for Senores Pharmaceuticals is scheduled to launch on December 20, 2024. With a Mainline IPO, ₹582.11 crores will be raised. The market lot of 38 shares for Senores Pharmaceuticals Services’ initial public offering (IPO) is set at ₹372 to ₹391.
The Senores Pharmaceuticals IPO, a ₹582.11 Cr mainline IPO, would be available for subscription from December 20 to December 24, 2024. The IPO includes a ₹82.11 Cr offer for sale and a ₹500.00 Cr fresh issue. The price range for each share is set at 372.00–391.00, with a face value of Rs 10. For a minimum lot of 38 shares totaling Rs 14858, you can apply to the Senores Pharmaceuticals Mainline IPO.
Senores Pharmaceuticals IPO Details
| IPO Open Date | December 20, 2024 |
| IPO Close Date | December 24, 2024 |
| Listing Date | Monday, December 30, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share |
| Lot Size | 38 Shares |
| Total Issue Size | 1,48,87,723 shares
(aggregating up to ₹582.11Cr) |
| Fresh Issue | 1,27,87,723 shares (aggregating up to ₹ 500.00Cr) |
| Offer for Sale | 21,00,000 shares of ₹10
(aggregating up to ₹82.11Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Senores Pharmaceuticals Financials Analysis
The financial year that ended on March 31, 2024, saw Senores Pharmaceuticals Limited’s revenue climb by 457% and its profit after tax (PAT) increase by 288%.
| FY 2024 | |
| Assets | 678.08 |
| Revenue | 183.35 |
| Profit After Tax | 23.94 |
| Net Worth | 319.06 |
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt/Equity | 1.07 |
| RoNW | 23.60% |
| PAT Margin | 15.25 |
| Price to Book Value | 5.84 |
About the Company – Pharmaceuticals
Senores Pharmaceuticals Limited is a multinational pharmaceutical company that is driven by research and is primarily focused on creating and producing a broad range of pharmaceutical products for the US and Canadian Regulated Markets. In forty-three countries, the corporation is also well-represented in emerging markets. Many clients choose it as their preferred partner because of its core competency, which is the identification and production of complex, underpenetrated, and niche pharmaceutical goods.
Senores Pharmaceuticals strategically finds commercially underpenetrated compounds to launch pharmaceuticals in both Regulated and Emerging Markets by data analytics, market assessment, and skilled management. The business uses its R&D resources to develop a line of sophisticated, unique medicinal items.
